Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (Weighted Average) (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $118.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 4.49% year-over-year to $118.8 million, compared with a TTM value of $118.8 million through Dec 2025, up 4.49%, and an annual FY2025 reading of $118.8 million, up 4.49% over the prior year.
  • Shares Outstanding (Weighted Average) was $118.8 million for Q4 2025 at Fate Therapeutics, roughly flat from $118.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $118.8 million in Q4 2025 and bottomed at $93.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $103.7 million, with a median of $98.3 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 23.12% in 2021, then increased 0.74% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $94.7 million in 2021, then grew by 2.19% to $96.8 million in 2022, then grew by 1.64% to $98.4 million in 2023, then grew by 15.52% to $113.7 million in 2024, then increased by 4.49% to $118.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for FATE at $118.8 million in Q4 2025, $118.6 million in Q3 2025, and $118.5 million in Q2 2025.